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Elevated activity of plasminogen activator inhibitor-1 (PAI-1) and decreased tissue plasminogen activator (tPA) activity are
considered to be important risk factors for type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS). The aim of this
study was to investigate the association of the PAI-14G/5G and tPA Alu-repeat I/D polymorphisms with T2DM in Malaysian
subjects. Serum insulin, coronary risk panel, plasma glucose, and PAI-14G/5G and tPA Alu-repeat I/D polymorphisms were
studiedin303T2DMsubjects(227withMetSand76withoutMetS)and131normalsubjectswithoutdiabetesandMetS.Statistical
analysis showed that the dominant and additive models of PAI-14G/5G polymorphism showed a weak association with T2DM
without MetS (OR = 2.35, P = 0.045; OR = 1.67, P = 0.058). On the other hand, the recessive model of the tPA Alu-repeat I/D
polymorphism showed an association with T2DM with MetS (OR = 3.32, P = 0.013) whereas the dominant and additive models
of the tPA Alu-repeat I/D polymorphism were not associated with T2DM either with or without MetS.
1.Background
Diabetes mellitus is the most common endocrine disorder
that aﬀects 246 million people worldwide. The International
Diabetes Federation (IDF) predicts that the number of
people with diabetes mellitus will increase up to 380 million
within twenty years [1]. Diabetes, mostly type 2 diabetes
mellitus (T2DM), now aﬀects 5.9% of the world’s adult
population with almost 80% of patients from developing
countries [2]. More than 1.3 million of Malaysians have
diabetes, and IDF predicts that this number would double
by 2025 [1]. The number of individuals with the metabolic
syndrome (MetS) has increased globally during the past two
decades, and this increase is associated with the worldwide
epidemic of obesity and diabetes [3].
Endothelial dysfunction is an emerging risk factor for
type 2 diabetes. Obesity, together with the MetS, has a
strong association with high PAI-1 levels [4–6]. Increased
levels of proinsulin, C-peptide, and insulin have also been
associated with high concentration of PAI-1 [7]. Recently,
we reported that elevated plasma PAI-1, and reduced tPA
activities were associated with an increased risk for T2DM
among Malaysian subjects [6]. Several PAI-1 gene SNPs
have been identiﬁed [8], among which the 4G/5G polymor-
phism (rs1799889) located in the promoter region −675bp
upstreamfromthemRNAsynthesisinitiationpointhasbeen
studied. Association of PAI-1 4G/5G polymorphism and
variables related to the MetS were, however, unclear with
carriers of the 4G allele being more prone to obesity and
MetS in some studies [8–10] but not in others [11–13].
Alu-repeat I/D polymorphism was found in intron 8 of
the tPA gene [14], and a number of populations have been
found to be dimorphic for its presence or absence of repeats2 Journal of Biomedicine and Biotechnology
[15]. The association of PAI-1 with T2DM has not been
reported in Malaysian subjects, and there is limited data on
the association of Alu-repeat I/D polymorphism with T2DM
worldwide. We studied the association of the PAI-1 4G/5G
and tPA Alu-repeat I/D polymorphisms with T2DM with or
without MetS as well as total T2DM in Malaysian subjects.
2.MaterialsandMethods
2.1. Subjects and Data Collection. For this study, a total of
434 Malaysian subjects aged 30–60 years were recruited.
Diabetic subjects were randomly recruited from patients
previously diagnosed with type 2 diabetes mellitus, who
received treatment at the University Malaya Medical Centre
(UMMC). After providing written informed consent, 303
T2DM subjects agreed to participate. Application of IDF
criteria [16] resulted in 227 of T2DM with MetS and 76
without MetS.
In general, subjects (diabetic and normal) with acute or
chronic infections, severe medical conditions (malignancy,
renal failure, liver cirrhosis, connective tissue disease, and
chronic congestive heart failure), and pregnant women were
excluded from the study.
For the control group, the consent forms and brochures
were distributed to the civil servant of the main oﬃce of
Radio and Television Malaysia at Bukit Putra, Angkasapuri,
Kuala Lumpur, Malaysia, through the Human Resource
Department. In addition, consent forms and brochures were
distributed to subjects who came to UMMC for medical
checkup. After providing written informed consent, 190
normal subjects were randomly recruited for this study.
Application of IDF criteria (for diagnose metabolic syn-
drome) [16] and WHO/IDF diagnosis of diabetes (FBG <
6.1mmol/L) [17] resulted in 131 subjects considered normal
(without diabetes and metabolic syndrome).
The Medical Ethics Committee of UMMC approved the
study. Fasting venous blood (6mL) was collected from each
subject after signed consent form. The collected blood was
immediately taken into three labelled Vacutainer sodium
ﬂuoride (for glucose measurement), plain (for insulin and
lipid proﬁle), and EDTA tubes (for genetic analysis).
2.2. Biochemical Analysis. Serum TG, HDL-c, and plasma
glucose were measured by an automated analyzer Dimension
RxL Max Integrated Chemistry System. Insulin was mea-
sured by ADVIA Centaur assay XP Immunoassay System
(Siemens Healthcare Diagnostics Inc. Deerﬁeld, IL, USA).
All these investigation were done at Division of Laboratory
Medicine (LMC) of the UMMC, Kuala Lumpur, Malaysia.
Insulin resistance (IR) was calculated using the homeostasis
model assessment (HOMA2) calculator v2.2 which is avail-
able from the Oxford Centre for Diabetes, Endocrinology
and Metabolism.
2.3.GeneticAnalysis. LeukocytegenomicDNAwasextracted
from whole EDTA blood using a commercially Wizard
Genomic DNA Puriﬁcation Kit (Promega Corporation,
Madison, WI, USA) according to the manufacturer’s instruc-
tions.
2.3.1. Genotyping of PAI-1 Polymorphisms. Allele-specif-
ic PCR was used to detect the genotypes of PAI-1
4G/5G. Two speciﬁc forward allele primers 5G, 5 -
GAGTCTGGACACGTGGGGG-3  at 3  e n di sG ,a n d4 G ,5  -
GAGTCTGGACACGTGGGGA-3  at 3  end the 5th G was
replaced by A as matching the subsequent sequence, were
designed to detect this SNP. An internal control was included
with each PCR reaction to ensure that there was PCR
ampliﬁcation. Therefore, common forward (upstream of
allele-speciﬁc primers 5 -TGGTCCCGTTCAGCCACCA-3 )
and reverse primers (downstream of allele-speciﬁc primers
5 -ATGCAGCCAGCCACGTGAT-3 ) were used as PCR am-
pliﬁcation controls with each PCR reaction. The reverse
primer also is a reverse primer for the two allele-speciﬁc
primers. Ampliﬁcation reactions of PAI-1 were performed
in two separated PCR reactions using 20µLv o l u m eo f
PCR contained 50ng of genomic DNA, 5pmol of allele-
speciﬁcprimer5Gor4G,1.2pmolofforwardprimer,5pmol
of reverse primer, 1.5mM MgCl2, 1X PCR buﬀer, 1X Q-
Solution, 100µM dNTPs, and 0.5 unit of HotStarTaq Plus
DNA Polymerase (Qiagen, Valencia, CA, USA). DNA was
denaturated at 94◦C for 5min, followed by 25 cycles of
denaturation at 94◦C for 1min, annealing at 63◦Cf o r4 5s e c ,
and extension at 70◦C for 75sec, with a ﬁnal extension
step for 5min at 72◦C. The PCR products were run by
electrophoresis in a 7% polyacrylamide gel (PAG) and
stained with ethidium bromide (EtBr). Band was visualized
by the gel document system (Inﬁnity 3026, Vilber Lourmat,
Marne-la-Vall´ ee, France).
2.3.2. Genotyping of tPA Polymorphism. An I/D polymor-
phism resulting from the presence or absence of Alu-
repeat in intron 8 of the tPA gene was assessed by
PCR using the following primers [18]. sense primer: 5 -
GTGAAAAGCAAGGTCTACCAG-3  and nonsense primer:
5 -GACACCGAGTTCATCTTGAC-3 .P C Rr e a c t i o nw a s
performed in a 20µLv o l u m ew i t h1 0p m o lo fe a c hp r i m e r ,
200µMd N T P ,3m MM g C l 2,1 XP C Rb u ﬀer, 1X Q-Solution,
1 unit HotStarTaq Plus DNA polymerase, and 50ng genomic
DNA. The samples were initially denaturated at 94◦Cf o r
5min before being subjected to 30 cycles consisting of 1min
at 94◦C (denaturation), 1min at 60◦C (annealing), and
75sec at 71◦C (extension) in a thermal cycler followed by
ﬁnal extension at 72◦C for 10min. 9µLo fe a c hp r o d u c tw e r e
electrophoresed on a 1% agarose gel, then stained by EtBr
and visualized by the gel document system.
Tovalidatetheobtainedresults,samplesofPCRproducts
(64ofPAI-1and46oftPA)weresenttoBioneerCorporation
(Daejeon, Republic of Korea) for sequencing. The sequenc-
ing results were in a good agreement with the PCR results.
No errors in allele-speciﬁc PCR were detected.
2.4. Statistical Analysis. Calculations to determine whether
observed genotype frequencies are consistent with the
Hardy-Weinberg equilibrium (HW) that was done by theJournal of Biomedicine and Biotechnology 3
Table 1: Demographic and biochemical parameters among normal and type 2 diabetes mellitus with or without metabolic syndrome
subjects.
Parameters Normal (n = 131) Type 2 diabetes mellitus
Without MetS (n = 76) With MetS (n = 227)
Gender %
Male/female 34.6/65.4 56.6/43.4 42.7/57.3
Races %
Malay 52.3 47.4 49.8
Chinese 33.75 23.7 14.5
Indian 13.75 28.9 35.7
Age (years) 49.1 ± 12.6 50.7 ± 9.0 51.9 ± 6.9
Body mass index (kg/m2) 23.0 ± 3.8 23.7 ± 4.0 30.0 ± 4.2
Waist circumference (cm) 79.9 ± 11.0 83.5 ± 10.3 98.9 ± 8.5
Diastolic blood pressure (mmHg) 80.4 ± 9.0 79.8 ± 9.4 83.7 ± 10.3
Systolic blood pressure (mmHg) 132 ± 18 131 ± 18 138 ± 18
Triglyceride (mmol/L) 1.15 ± 0.56 1.55 ± 1.21 1.98 ± 1.25
High-density lipoprotein (mmol/L) 1.57 ± 0.37 1.24 ± 0.31 1.17 ± 0.27
Fasting blood glucose (mmol/L) 5.04 ± 0.51 8.55 ± 3.34 8.20 ± 3.15
Insulin (pmol/L) 53.3 ± 35.5 89.4 ± 85.9 150 ± 104
Insulin resistance (IR) 1.00 ± 0.66 1.82 ± 1.68 3.00 ± 1.98
The result presented as mean ± standard deviation. MetS: metabolic syndrome. T: total.
Table 2: Association of PAI-1 4G/5G polymorphisms with type 2 diabetes mellitus in Malaysian subjects.
PAI-1 4G/5G polymorphism Control (n = 131)
Type 2 diabetes mellitus
Total type 2 diabetes mellitus
(n = 303) Without MetS
(n = 76)
With MetS
(n = 227)
Risk allele frequency (4G) 0.47 0.48 0.49 0.50
(4G/4G)/(4G/5G)/(5G/5G) (frequency) 0.23/0.485/0.29 0.25/0.54/0.21 0.25/0.48/0.27 0.25/0.50/0.25
Recessive model
Odds ratio 1.8 0.66 0.78
95% CI (0.77–4.2) (0.31–1.4) 0.37–1.66
P value 0.17 0.29 0.52
Dominant model
Odds ratio 2.35 1.61 1.5
95% CI 1.0–5.43 (0.9–2.91) 0.72–1.7
P value 0.045 0.11 0.28
Additive model
Odds ratio 1.67 1.1 1.1
95% CI 0.98–2.84 0.75–1.6 0.69–1.74
P value 0.058 0.63 0.69
In the additive model, genotype of homozygote for the nonrisk allele 5G/5G (0/0), heterozygote 4G/5G (1/0), and homozygote for the risk allele 4G/4G (1/1)
w e r ec o d e da s0 ,1 ,a n d2 ,r e s p e c t i v e l y .T h er e c e s s i v em o d e lw a sd e ﬁ n e da s4G/4G versus (4G/5G + 5G/5G), dominant model as (4G/4G + 4G/5G) versus
5G/5G, and additive model as 4G/4G versus 4G/5G versus 5G/5G. The results presented odds ratio, 95% CI, and P value adjusted for age, gender, race, family
history of diabetes, and BMI as covariates which evaluated by hierarchical logistic regression. MetS: metabolic syndrome.
method of Court (2005, 2008). All other statistical analyses
were done using Social Package of Statistical Science (SPSS)
11.5 (LEAD Technologies, Inc., USA). The missing data were
listwise deleted—when any of the variables were missing,
the entire observation was omitted from the analysis. The
associations of the PAI-1 and tPA polymorphisms, recessive,
dominant, and additive models with T2DM with or without
MetS and total T2DM were evaluated by hierarchical logistic
regression controlled for age, gender, race, history of dia-
betes, and BMI as covariates. The diﬀerence between means
was considered signiﬁcant when P value <0.05.
3. Results
The demographic and biochemical parameters of the sub-
jects are shown in Table 1.
The frequency of the minor allele (4G) of PAI-1 (0.47)
was lower than that of the 5G allele (0.53), whereas the
frequency of tPA allele insertion (0.48) was lower than that
of the allele deletion (0.52).
The results showed that the dominant and additive
models of PAI-1 4G/5G polymorphism showed a weak
associationwithT2DMwithoutMetS(OR =2.35,P = 0.045;
OR = 1.67, P = 0.058), with no association for T2DM with
MetS and total T2DM. Further, the recessive model showed
no association of PAI-1 4G/5G genotype with T2DM with or
without MetS (Table 2). On the other hand, the dominant
and additive models of tPA Alu-repeat I/D were not a
risk for T2DM with or without MetS and total T2DM. In
contrast, the recessive model of tPA Alu repeat I/D genotype
showed a risk factor for T2DM with MetS (OR = 3.32,4 Journal of Biomedicine and Biotechnology
Table 3: Association of tPA Alu repeat-I/D polymorphism with type 2 diabetes mellitus in Malaysian subjects.
tPA Alu repeat I/D polymorphism Control (n = 131)
Type 2 diabetes mellitus
Total type 2 diabetes mellitus
(n = 303) Without MetS
(n = 76)
With MetS
(n = 227)
Risk allele frequency (Insertion) 0.48 0.47 0.50 0.49
II/ID/DD (frequency) 0.23/0.49/0.28 0.28/0.50/0.22 0.26/0.48/0.26 0.25/0.49/0.26
Recessive model
Odds ratio 1.88 3.32 1.34
95% CI 0.81–4.4 1.28–8.57 0.66–2.9
P value 0.14 0.013 0.39
Dominant model
Odds ratio 1.02 1.21 1.27
95% CI 0.44–2.37 0.51–2.9 0.61–2.65
P value 0.96 0.66 0.52
Additive model
Odds ratio 1.28 1.48 1.24
95% CI 0.77–2.13 0.87–2.51 0.8–1.7
P value 0.34 0.15 0.34
In the additive model, genotype of homozygote for the nonrisk allele D/D (0/0), heterozygote I/D (1/0), and homozygote for the risk allele I/I (1/1) wasc o d e d
as 0, 1, and 2, respectively. The recessive model was deﬁned as I/I versus (I/D + D/D), dominant model as (I/I + I/D) versus D/D and additive model as D/D,
versus I/D versus I/I. The results presented odds ratio, 95% CI and P-value adjusted for age, gender, race, family history of diabetes and BMI as covariates
which evaluated by hierarchical logistic regression. MetS: metabolic syndrome.
P = 0.013) with no association for T2DM without MetS and
total T2DM (Table 3). The association of PAI-1 4G/5G and
tPA Alu repeat I/D polymorphisms with T2DM showed no
signiﬁcantdiﬀerenceswhenstatisticallyanalyzedadjustedfor
age, gender, race, and family history of diabetes as covariate
without BMI (see Supplementary Tables S1 and S2 available
online at doi:10.1155/2012/234937). Results were not altered
by further adjustment for speciﬁc medications for hyper-
lipidaemia, hypertension, and hyperglycaemia. Univariate
analyses showed that the PAI-1 4G/5G and tPA Alu-repeat
I/Dpolymorphisms werenotassociatedwiththeageofonset
of diabetes (Supplementary Table S3).
4. Discussion
The association of the PAI-1 4G/5G and tPA Alu-repeat
I/D polymorphisms with T2DM with or without MetS as
well as with total T2DM was studied in Malaysian subjects.
In this study, there were no diﬀerences in the frequencies
of both polymorphisms PAI-1 4G/5G and tPA Alu-repeat
I/D between T2DM and normal subjects. The analysis of
genetic models of PAI-1 4G/5G polymorphism (dominant
and additive) showed a weak association of polymorphism
withT2DMinMalaysiansubjects.Thisweakassociationmay
be due to small sample size, particularly in the control group,
and nonmatched gender. On the other hand, the recessive
modelofPAI-14G/5Gpolymorphismshowednoassociation
with T2DM in Malaysian subjects.
Previous studies had shown signiﬁcant association with
T2DM among the Chinese [19], Tunisian [20], and Pima
Indiansubjects[21].However,otherstudiesonCaucasian[8,
22–24], Japanese [25], and Framingham subjects [26]h a v e
reported that PAI-1 4G/5G polymorphism is not associated
with T2DM. This variability of the genetic association can be
explained, in part, by diﬀerences in the characterization of
diabetic patients. In our study, patients were characterized as
T2DM with or without MetS, whereas in the studies of Wong
et al. (2000) [19] and Ezzidi et al. (2009) [20]s u b j e c t sw e r e
grouped as T2DM with nephropathy while in the study of
Nagi et al. (1997) [21] subjects had T2DM with retinopathy.
In addition, ethnicity and environmental factors may alter
the phenotypic expression of the genes. Furthermore, our
previous study reported that the plasma PAI-1 activity
was signiﬁcantly higher in Malaysian diabetic subjects with
metabolic syndrome than normal [6]. In addition, we
demonstrated that the level of plasma PAI-1 was higher in
Malaysian normal subjects with homozygous 4G/4G and
heterozygous 4G/5G compared to PAI-1 homozygous 5G/5G
genotypes [27].
Genetic data in this study also showed that no diﬀerences
existed in the allelic frequencies of the insertion and deletion
alleles between T2DM with or without MetS as well as total
T2DM and normal groups. On the other hand, the recessive
model, of the tPA Alu-repeat I/D polymorphism showed a
risk factor for T2DM. However, there is limited data on
the association of tPA Alu-repeat I/D polymorphism with
diseases, while there are no available data on its association
with T2DM. Further, its association with other diseases
such as myocardial infarction [28], multiple sclerosis [29]
and periodontitis [30] has been described. The analysis of
these results showed that there is no association between the
genetic polymorphisms of PAI-1 4G/5G and tPA Alu-repeat
I/D and the age of onset of diabetes.
5. Conclusion
ThedominantmodelofPAI-14G/5Gpolymorphismshowed
a weak association with T2DM without MetS. On the
other hand, the recessive model of tPA Alu repeat I/D
polymorphism showed a risk factor for T2DM with MetS in
Malaysian subjects.Journal of Biomedicine and Biotechnology 5
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